(Q37720886)

22 August 2017

1 reference

title

Rituximab-associated neutropenia (English)

1 reference

22 August 2017

3

Wyndham H Wilson

1 reference

22 August 2017

Kieron Dunleavy

1

1 reference

22 August 2017

Kevin Tay

series ordinal

2

1 reference

22 August 2017

publication date

1 April 2010

1 reference

22 August 2017

published in

Seminars in Hematology

1 reference

22 August 2017

volume

47

1 reference

22 August 2017

issue

2

1 reference

22 August 2017

page(s)

180-186

1 reference

B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis

22 August 2017

cites work

1 reference

12 December 2020

Increased level of stromal cell-derived factor-1 mRNA in peripheral blood mononuclear cells from children with AIDS-related lymphoma

1 reference

12 December 2020

IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma

1 reference

12 December 2020

Stages of B cell differentiation in human lymphoid tissue

1 reference

12 December 2020

The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment

1 reference

12 December 2020

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

12 December 2020

Role of the CXCR4/SDF-1 chemokine axis in circulating neutrophil homeostasis

1 reference

12 December 2020

Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development

1 reference

12 December 2020

Chemokines acting via CXCR2 and CXCR4 control the release of neutrophils from the bone marrow and their return following senescence

1 reference

12 December 2020

Serum inactivation contributes to the failure of stromal-derived factor-1 to block HIV-I infection in vivo

1 reference

12 December 2020

Late-onset neutropenia following rituximab treatment in patients with autoimmune diseases

1 reference

12 December 2020

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

12 December 2020

Intracellular and surface expression of the HIV-1 coreceptor CXCR4/fusin on various leukocyte subsets: rapid internalization and recycling upon activation.

1 reference

12 December 2020

The earliest stages of B cell development require a chemokine stromal cell-derived factor/pre-B cell growth-stimulating factor.

1 reference

12 December 2020

Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1

1 reference

12 December 2020

T-cell large granular lymphocyte leukemia and related disorders

1 reference

12 December 2020

Chromosomal abnormalities in T-cell large granular lymphocyte leukaemia: report of two cases and review of the literature

1 reference

12 December 2020

Cellular niches controlling B lymphocyte behavior within bone marrow during development.

1 reference

12 December 2020

1 reference

12 December 2020

Characterization of a human B lymphocyte-specific antigen.

1 reference

12 December 2020

Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment

1 reference

12 December 2020

Neutropenia in patients treated with rituximab

1 reference

12 December 2020

Rituximab-associated immune myelopathy

1 reference

12 December 2020

Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells

1 reference

12 December 2020

Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments

1 reference

12 December 2020

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

1 reference

12 December 2020

Delayed-onset neutropenia associated with rituximab therapy

1 reference

12 December 2020

Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery.

1 reference

12 December 2020

Evidence for T-large granular lymphocyte-mediated neutropenia in Rituximab-treated lymphoma patients: report of two cases

1 reference

12 December 2020

CD20: a regulator of cell-cycle progression of B lymphocytes

1 reference

12 December 2020

Rituximab dose-escalation trial in chronic lymphocytic leukemia

1 reference

12 December 2020

A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study

1 reference

12 December 2020

Late-onset neutropenia following RCHOP chemotherapy in diffuse large B-cell lymphoma.

1 reference

12 December 2020

Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma

1 reference

12 December 2020

Rituximab in non-haematological disorders of adults and its mode of action

1 reference

12 December 2020

10.1053/J.SEMINHEMATOL.2010.01.009

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/dzw2jn7uufarpjw7qy3ihnauaq

30 July 2022

release_dzw2jn7uufarpjw7qy3ihnauaq

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/dzw2jn7uufarpjw7qy3ihnauaq

30 July 2022

https://api.fatcat.wiki/v0/release/dzw2jn7uufarpjw7qy3ihnauaq

1 reference

30 July 2022

https://api.fatcat.wiki/v0/release/dzw2jn7uufarpjw7qy3ihnauaq

1 reference

30 July 2022